Biological and pharmacological aspects of borderline personality disorder.
Biological and pharmacological aspects of borderline personality disorder.
复制标题
边缘性人格障碍的生物学和药理学方面。
DOI：
10.1176/ps.42.10.1029
复制
发表时间：
1991
期刊：
影响因子：
--
通讯作者：
Kavoussi,RJ
中科院分区：
文献类型：
--
作者：
Coccaro,EF;Kavoussi,RJ
生物学和精神药理学研究集中在边缘型人格障碍的DSM-III-R诊断的患者表明，该障碍可能包括三个集群的情感不稳定，短暂的精神病现象，冲动的攻击行为，有不同的潜在的生物基板，响应不同类别的药物。情感不稳定，这可能与大脑的肾上腺素能和胆碱能系统的异常有关，似乎对治疗主要情感障碍有效的药物如锂和卡马西平有反应。中枢多巴胺能系统的抑制可能是短暂性精神病症状的基础。这种关系与低剂量抗精神病药物治疗某些边缘患者的有益效果的报告一致。中枢神经系统的兴奋性功能异常似乎是攻击性行为的基础。这些行为可能对氟西汀等阿片类药物有反应。
Biological and psychopharmacological research focusing on patients with a DSM-III-R diagnosis of borderline personality disorder suggests that the disorder may encompass three clusters of symptoms—affective instability, transient psychotic phenomena, and impulsive aggressive behavior—that have different underlying biological substrates that respond to different classes of pharmacological agents. Affective instability, which may be related to abnormalities in the brain's adrenergic and cholinergic systems, appears to respond to agents such as lithium and carbamazepine that are effective in treating major affective disorders. Abnormalities in central dopaminergic systems may underlie transient psychotic symptoms. This relationship is consistent with reports of beneficial effects of low-dose neuroleptics in treating some borderline patients. Abnormalities in central nervous system serotonergic functioning appear to underlie impuhive aggressive behaviors. These behaviors may respond to serotonergic agents such as fluoxetine.